<DOC>
	<DOCNO>NCT00004789</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate efficacy safety heme arginate treatment 20 patient acute attack porphyria . II . Evaluate efficacy safety heme arginate prevent frequent exacerbation acute porphyria 15 patient . III . Estimate low effective dose heme arginate ( 0.3 , 1.0 , 3.0 mg/kg ) reduce porphyrin precursor 12 stable patient acute intermittent porphyria remission . IV . Evaluate safety efficacy tin mesoporphyrin use combination heme arginate reduce porphyrin precursor 12 stable patient acute intermittent porphyria remission .</brief_summary>
	<brief_title>Phase I/II Study Heme Arginate Tin Mesoporphyrin Acute Porphyria</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This project involve 4 study : unblinded multicenter treatment study , unblinded prevention study , control dose-ranging study , control drug combination dose-ranging study . In treatment study , participant acute attack porphyria receive intravenous heme arginate daily 4 day . Treatment may extend 7 day patient severe attack slow recovery ; data analyze separately . In prevention study , participant receive weekly infusion heme arginate 6 month . Treatment may extend select case ; data analyze separately . If acute attack occurs , patient treat standard course heme arginate . Participants follow weekly 6 month preventive treatment . In dose-ranging study , 4 group 3 patient randomly assign standard low-dose heme arginate infusion , administer daily 4 day . After washout 4-12 week , patient cross second dose . In 2 4 group , patient cross heme arginate normal saline control . In combination dose-ranging study , 4 group 3 patient randomly assign 1 2 dos tin mesoporphyrin . After 4-12 week washout , patient cross standard low-dose heme arginate infusion . After second 4-12 week washout , patient give combination infusion tin mesoporphyrin follow heme arginate . All participant give special diet prevent fluctuation porphyrin precursor .</detailed_description>
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria , Erythropoietic</mesh_term>
	<mesh_term>Tin mesoporphyrin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Welldocumented acute porphyria , i.e . : Acute intermittent porphyria Variegate porphyria Hereditary coproporphyria Patient Characteristics No pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>inborn error metabolism</keyword>
	<keyword>acute porphyria</keyword>
	<keyword>rare disease</keyword>
</DOC>